An extended regimen for treatment of HER-2neu overexpressedamplified cancer is described, with involves delivering a course of neratinib therapy to HER-2neu overexpressedamplified cancer patients following the completion of surgical and adjuvant therapy. The hematopoietic-inducing environment can be either ex vivo or in vivo. The orientation layer is subjected to rubbing treatment. A second insulating layer covers the intercepting trench and the substrate where the gate line and the gate electrode are not formed.